Tags

Type your tag names separated by a space and hit enter

Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):695-704.IJ

Abstract

PURPOSE

To investigate the potential effect of using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in the initial assessment of patients with clinical Stage II or III breast cancer.

METHODS AND MATERIALS

During 14 consecutive months, 39 patients (40 tumors) who presented with Stage II or III breast cancer on the basis of a routine extension assessment were prospectively included in this study. PET/CT was performed in addition to the initial assessment.

RESULTS

In 3 cases, PET/CT showed extra-axillary lymph node involvement that had not been demonstrated with conventional techniques. Two of these patients had hypermetabolic lymph nodes in the subpectoral and infraclavicular regions, and the third had a hypermetabolic internal mammary node. PET/CT showed distant uptake in 4 women. Of these 4 women, 1 had pleural involvement and 3 had bone metastasis. Overall, of the 39 women, the PET/CT results modified the initial stage in 7 (18%). The modified staging altered the treatment plan for 5 patients (13%). It led to radiotherapy in 4 patients (bone metastasis, pleural lesion, subpectoral lymph nodes, and internal mammary nodes) and excision of, and radiotherapy to, the infraclavicular lymph nodes in 1 patient.

CONCLUSIONS

PET/CT can provide information on extra-axillary lymph node involvement and can uncover occult distant metastases in a significant percentage of patients. Therefore, initial PET/CT could enable better treatment planning for patients with Stage II and III breast cancer.

Authors+Show Affiliations

Department of Nuclear Medicine, Breast Diseases Unit, Saint Louis Hospital, Paris, France. dgroheux@yahoo.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18436392

Citation

Groheux, David, et al. "Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer." International Journal of Radiation Oncology, Biology, Physics, vol. 71, no. 3, 2008, pp. 695-704.
Groheux D, Moretti JL, Baillet G, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008;71(3):695-704.
Groheux, D., Moretti, J. L., Baillet, G., Espie, M., Giacchetti, S., Hindie, E., Hennequin, C., Vilcoq, J. R., Cuvier, C., Toubert, M. E., Filmont, J. E., Sarandi, F., & Misset, J. L. (2008). Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. International Journal of Radiation Oncology, Biology, Physics, 71(3), 695-704. https://doi.org/10.1016/j.ijrobp.2008.02.056
Groheux D, et al. Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):695-704. PubMed PMID: 18436392.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. AU - Groheux,David, AU - Moretti,Jean-Luc, AU - Baillet,Georges, AU - Espie,Marc, AU - Giacchetti,Sylvie, AU - Hindie,Elif, AU - Hennequin,Christophe, AU - Vilcoq,Jacques-Robert, AU - Cuvier,Caroline, AU - Toubert,Marie-Elisabeth, AU - Filmont,Jean-Emmanuel, AU - Sarandi,Farid, AU - Misset,Jean-Louis, Y1 - 2008/04/23/ PY - 2008/01/01/received PY - 2008/02/15/revised PY - 2008/02/16/accepted PY - 2008/4/26/pubmed PY - 2008/7/26/medline PY - 2008/4/26/entrez SP - 695 EP - 704 JF - International journal of radiation oncology, biology, physics JO - Int J Radiat Oncol Biol Phys VL - 71 IS - 3 N2 - PURPOSE: To investigate the potential effect of using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in the initial assessment of patients with clinical Stage II or III breast cancer. METHODS AND MATERIALS: During 14 consecutive months, 39 patients (40 tumors) who presented with Stage II or III breast cancer on the basis of a routine extension assessment were prospectively included in this study. PET/CT was performed in addition to the initial assessment. RESULTS: In 3 cases, PET/CT showed extra-axillary lymph node involvement that had not been demonstrated with conventional techniques. Two of these patients had hypermetabolic lymph nodes in the subpectoral and infraclavicular regions, and the third had a hypermetabolic internal mammary node. PET/CT showed distant uptake in 4 women. Of these 4 women, 1 had pleural involvement and 3 had bone metastasis. Overall, of the 39 women, the PET/CT results modified the initial stage in 7 (18%). The modified staging altered the treatment plan for 5 patients (13%). It led to radiotherapy in 4 patients (bone metastasis, pleural lesion, subpectoral lymph nodes, and internal mammary nodes) and excision of, and radiotherapy to, the infraclavicular lymph nodes in 1 patient. CONCLUSIONS: PET/CT can provide information on extra-axillary lymph node involvement and can uncover occult distant metastases in a significant percentage of patients. Therefore, initial PET/CT could enable better treatment planning for patients with Stage II and III breast cancer. SN - 0360-3016 UR - https://www.unboundmedicine.com/medline/citation/18436392/Effect_of__18_F_FDG_PET/CT_imaging_in_patients_with_clinical_Stage_II_and_III_breast_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0360-3016(08)00427-6 DB - PRIME DP - Unbound Medicine ER -